

Contents

ABOUT THE EDITORS — **v**

HISTORICAL DEVELOPMENT
AND PERSPECTIVES OF THE SERIES — **vii**

PREFACE TO VOLUME 18 — **ix**

CONTRIBUTORS TO VOLUME 18 — **xix**

TITLES OF VOLUMES 1–44 IN THE
METAL IONS IN BIOLOGICAL SYSTEMS SERIES — **xxiii**

CONTENTS OF VOLUMES IN THE
METAL IONS IN LIFE SCIENCES SERIES — **xxv**

Imogen A. Riddell and Stephen J. Lippard

1 CISPLATIN AND OXALIPLATIN: OUR CURRENT
UNDERSTANDING OF THEIR ACTIONS — **1**

Abstract — **2**

1. Introduction — **2**

2. Cellular Uptake and Efflux/Membrane Transport — **6**

3. Covalent Adducts Generated with Platinum Agents — **13**

4. Cellular Processing of Platinum DNA Adducts — **18**

5. Signal Transduction Pathways Activated by Platinum DNA
Damage — **25**

6. Undesired Consequences of Platinum-Based Chemotherapy — **30**

7. Concluding Remarks and Future Directions — **33**

Acknowledgments — **34**

Abbreviations and Definitions — **34**

References — **35**

Viktor Brabec, Jana Kasparikova, Vijay Menon, and Nicholas P. Farrell

2 POLYNUCLEAR PLATINUM COMPLEXES. STRUCTURAL
DIVERSITY AND DNA BINDING — **43**

Abstract — **44**

1. Introduction — **44**

2. Dinuclear Bifunctional Platinum(II) Complexes with Alkanediamine Linkers — **46**
 3. Polyamine-Linked Bifunctional Dinuclear Platinum(II) Complexes — **49**
 4. DNA-Protein Crosslinking — **53**
 5. Dinuclear Platinum(II) Complexes Stabilizing G-DNA Quadruplexes — **53**
 6. Structural Variation in Dinuclear Platinum(II) Complexes — **55**
 7. Trinuclear Platinum(II) Complexes — **56**
 8. Conclusions and Outlook — **62**
- Acknowledgments — **63**
 Abbreviations and Definitions — **63**
 References — **64**

V. Venkatesh and Peter J. Sadler

3 PLATINUM(IV) PRODRUGS — 69

Abstract — **70**

1. Introduction — **70**
2. Interactions with Biomolecules — **77**
3. Design Features for Anticancer Complexes — **80**
4. Photoactivatable Complexes — **88**
5. Nano Materials for Drug Delivery — **92**
6. Concluding Remarks — **101**

Acknowledgments — **102**

Abbreviations — **102**

References — **103**

*Nicholas P. Farrell, Anil K. Gorle,
 Erica J. Peterson, and Susan J. Berners-Price*

4 METALLOGLYCOMICS — 109

Abstract — **110**

1. Introduction. Metalloglycomics, Heparin, and Heparan Sulfate — **110**
2. Structure and Conformation of Heparin and Heparan Sulfate — **112**
3. Interaction of Metal Ions with Glycosaminoglycans — **118**
4. Interaction of Coordination Compounds with Glycosaminoglycans — **121**
5. Consequences of High-Affinity Heparan Sulfate Binding — **128**
6. Use of Metal Complexes in Heparin Analysis — **134**
7. Conclusions and Outlook — **135**

Acknowledgments — **135**

Abbreviations and Definitions — **135**

References — **136**

Enzo Alessio and Luigi Messori

- 5 THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS? — 141**

Abstract — **142**

1. Introduction — **142**
2. Comparison of NAMI-A and KP1019 — **145**
3. Conclusions and Outlook — **164**

Acknowledgments — **165**

Abbreviations and Definitions — **165**

References — **166**

Maria V. Babak and Wee Han Ang

- 6 MULTINUCLEAR ORGANOMETALLIC RUTHENIUM-ARENE COMPLEXES FOR CANCER THERAPY — 171**

Abstract — **172**

1. Introduction — **172**
2. Homoleptic Dinuclear Complexes — **174**
3. Homoleptic Trinuclear and Tetranuclear Complexes — **178**
4. Polynuclear Ruthenium-Arene Cages — **181**
5. Heteronuclear Ruthenium-Arene Complexes — **186**
6. Conclusions — **192**

Acknowledgments — **193**

Abbreviations — **193**

References — **194**

Angela Casini, Raymond Wai-Yin Sun, and Ingo Ott

- 7 MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS — 199**

Abstract — **200**

1. Introduction — **200**
2. Current Status of Registered Gold Drugs — **200**
3. Gold(I) Anticancer Drugs — **202**
4. Gold(III) Anticancer Drugs — **205**
5. Biological Functions of Gold Complexes — **208**
6. General Conclusions — **213**

Acknowledgments — **213**

Abbreviations and Definitions — **214**

References — **214**

Edit Y. Tshuva and Maya Miller

- 8 COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY — 219**

Abstract — **219**

1. Introduction — **220**
2. Cyclopentadienyl-Based Complexes — **221**

3. Budotitane and Related Diketonato Complexes — 227
4. Complexes of Phenolato Ligands — 230
5. Conclusions and Outlook — 237
- Acknowledgments — 240
- Abbreviations and Definitions — 240
- References — 240
- Debbie C. Crans, Lining Yang, Allison Haase, and Xiaogai Yang*
- 9 HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT — 251
- Abstract — 252
1. Introduction: Vanadium-Containing Compounds Induce Biological Actions — 252
2. Applications of Vanadium Compounds in Human Studies — 254
3. Biological Chemistry of Vanadium — 258
4. The Anticancer Effects of Vanadium Compounds — 262
5. Vanadium-Containing Drugs in Context of Other Diseases — 265
6. Vanadium-Based Drugs and Additives and Their Formulation — 267
7. Conclusions and Outlook — 272
- Acknowledgments — 273
- Abbreviations — 273
- References — 274
- Christopher R. Chitambar*
- 10 GALLIUM COMPLEXES AS ANTICANCER DRUGS — 281
- Abstract — 282
1. History — 282
2. Chemistry — 283
3. Gallium-Based Agents in Clinical Use. Pharmacology and Efficacy — 283
4. Cellular Handling of Gallium — 288
5. Antineoplastic Mechanism of Clinically Used Gallium Compounds — 290
6. Gallium Compounds in Preclinical Development — 294
7. Summary and Outlook — 296
- Acknowledgments — 297
- Abbreviations — 297
- References — 297
- Lucia Cardo and Michael J. Hannon*
- 11 NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES — 303
- Abstract — 304
1. Introduction — 304
2. Metallo-Cylinders — 304

3. Other Supramolecular Designs and Their Targets — **310**
 4. Concluding Remarks and Future Directions — **319**
- Acknowledgments — **320**
Abbreviations and Definitions — **320**
References — **321**

Ramon Vilar

- 12 NUCLEIC ACID QUADRUPLEXES AND METALLO-DRUGS — 325**
- Abstract — **325**
1. Introduction — **326**
 2. G-Quadruplexes and Their Biological Roles — **327**
 3. Metal Complexes as G-Quadruplex Binders — **328**
 4. Metal-Based Optical Probes for G-Quadruplexes — **338**
 5. Biological Activity of Metal-Based G-Quadruplex Binders — **340**
 6. Concluding Remarks and Future Directions — **344**
- Acknowledgments — **344**
Abbreviations — **344**
References — **345**

Matthew P. Sullivan, Hannah U. Holtkamp, and Christian G. Hartinger

- 13 ANTITUMOR METALLODRUGS THAT TARGET PROTEINS — 351**
- Abstract — **352**
1. Introduction — **352**
 2. Anticancer Metallo drugs that Target Carrier Proteins — **354**
 3. Selected Cancer-Related Proteins as Targets — **362**
 4. Non-Conventional Protein Targets for Anticancer Metallo drugs — **373**
 5. Modern Bioanalytical Methods — **375**
 6. Concluding Remarks and Future Directions — **376**
- Acknowledgments — **377**
Abbreviations — **377**
References — **379**

Ulrich Schatzschneider

- 14 METALLOINTERCALATORS AND METALLOINSERTORS:
STRUCTURAL REQUIREMENTS FOR DNA RECOGNITION AND
ANTICANCER ACTIVITY — 387**
- Abstract — **388**
1. Introduction — **388**
 2. The Basics: Nucleic Acid Structure and Enzymatic Processing — **389**
 3. Analytical Methods to Study Metal Complex-DNA Interactions — **394**
 4. Metallointercalators — **396**
 5. Metalloinsertors — **413**
 6. Concluding Remarks and Future Directions — **426**
- Abbreviations and Definitions — **427**
References — **430**

- Frank Thévenod*
- 15 IRON AND ITS ROLE IN CANCER DEFENSE: A DOUBLE-EDGED SWORD — 437**
Abstract — 438
1. Introduction — 438
2. Short Overview of Systemic and Cellular Iron Homeostasis — 439
3. Iron and Cancer Formation: “A Predominant Feature” — 441
4. Iron and Cancer Defense: “Long Live the Difference” — 444
5. General Conclusions — 456
Acknowledgments — 456
Abbreviations and Definitions — 456
References — 458
- Delphine Denoyer, Sharnel A. S. Clatworthy, and Michael A. Cater*
- 16 COPPER COMPLEXES IN CANCER THERAPY — 469**
Abstract — 470
1. Introduction — 470
2. Repurposing Old Copper Complexes for Cancer Treatment — 477
3. Emerging Classes of Copper Complexes for Cancer Treatment — 489
4. General Conclusions — 496
Acknowledgments — 497
Abbreviations — 497
References — 498
- Silvia Ziliotto, Olivia Ogle, and Kathryn M. Taylor*
- 17 TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER — 507**
Abstract — 507
1. Introduction — 508
2. Zinc Handling in Cells — 508
3. Zinc in Cancer — 513
4. Zinc Signalling in Cancer — 518
5. Targeting Zinc Signalling Mechanisms in Cancer — 520
6. General Conclusions — 523
Acknowledgments — 523
Abbreviations and Definitions — 524
References — 524
- SUBJECT INDEX — 531**